Patients with von Hippel-Lindau syndrome may represent another population of interest for future studies, given their predisposition to develop multiple CAIX-expressing tumours, including ccRCC, haemangioblastomas, and neuroendocrine tumours, all driven by VHL inactivation [57]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.